Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2022
Cassava Sciences sued over alleged data manipulation and investor statements
Plaintiff Patricia Matranga filed suit against Cassava Sciences' board and upper management, alleging violations of fiduciary duties. The complaint alleges that defendants caused the company to submit manipulated data to the FDA and made materially false and misleading statements to investors concerning simufilam.
2021
SEC reportedly investigates Cassava Sciences research claims
The article reports that the U.S. Securities and Exchange Commission is investigating claims that Cassava Sciences manipulated research results. Cassava said it was cooperating with government agencies that requested company information and documents.
2021
Cassava Sciences sued over Simufilam disclosures
Manhoar Rao filed a proposed class action against Cassava Sciences Inc. and two individuals in the Western District of Texas, alleging violations of federal securities law concerning disclosures about Simufilam. The complaint alleges that statements related to the drug’s clinical trials were false and fraudulent; no court determination is reported.